APOGEE THERAPEUTICS INC secured up to $1.3 billion from BLACKSTONE INC after mid-stage trial results for its eczema treatment zumilokibart. The drug achieved a 75% severity improvement in 65.9% of mid-dose patients, compared to 23.4% for the placebo group after 16 weeks. The capital allows Apogee to fund late-stage development without diluting shareholders through new equity offerings.
Apogee secures up to 1.3 billion dollars for eczema drug
Apogee Therapeutics secured up to 1.3 billion dollars from Blackstone for its eczema drug. Shares fell as mid-stage trial results showed mixed performance.
Xurve View
Insights:
Xurve View







